Please provide your email address to receive an email when new articles are posted on . Cerebral amyloid angiopathy was associated with a higher risk for isolated nontraumatic subdural hemorrhage in ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced additional positive interim results for the ongoing single ascending dose portion of the Phase 1 study ...

A 74-year-old man with an unremarkable medical history noted a progressive gait disorder in the months prior to admission. His wife recalled increased sleepiness and loss of initiative. After having ...

What triggers the vascular Aβ deposits known as cerebral amyloid angiopathy (CAA)? In the November 16 Nature, researchers led by Jonas Neher at the German Center for Neurodegenerative Diseases in ...

New research hints at the possibility that cerebral amyloid angiopathy (CAA), a cause of spontaneous brain hemorrhage, can be transmitted via blood transfusion, raising the risk for spontaneous ...

Research over the last decade has shown that aggregated Aβ seeds can be transferred between people during rare medical procedures, sparking amyloidosis in the recipient. Could this result in ...

Currently, there is no cure for amyloidosis, a life-threatening disease that can be present throughout the body, including the heart, kidneys, liver and brain. The most common localized form of ...

Currently, there is no cure for amyloidosis, a life-threatening disease that can be present throughout the body, including the heart, kidneys, liver and brain. The most common localized form of ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization ...

– First Patient Dosed in Multiple-dose Part B Portion of Study, with the Study Proceeding in Canada, UK, and the Netherlands – CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq ...